Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FSHR | P23945 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1656241 | 0.75 | NFKB1 (0.41) | GAANFKB1NFKB2RELACA1 | |
| SCHEMBL573575 | 0.72 | NFKB1 (0.39) | GAANFKB1NFKB2RELACA1 | |
| SCHEMBL1829582 | 0.72 | CYP17A1 (0.39) | GAANFKB1NFKB2RELACA1 | |
| SCHEMBL28167286 | 0.71 | GAA (0.38) | GAANFKB1NFKB2RELACA1 | |
| SCHEMBL4603098 | 0.71 | GAA (0.39) | GAANFKB1NFKB2RELACA1 | |
| SCHEMBL3344629 | 0.70 | BTK (0.47) | GAANFKB1NFKB2RELACA1 | |
| SCHEMBL28145038 | 0.70 | USP2 (0.37) | GAAHCRTR2SMN1; SMN2 | |
| SCHEMBL2947606 | 0.67 | GAA (0.34) | GAAHCRTR2HCRTR1NPC1RAB9A | |
| SCHEMBL12709302 | 0.67 | GAA (0.34) | GAACA2HCRTR2CA12 | |
| SCHEMBL1551115 | 0.67 | ALDH1A1 (0.40) | GAANFKB1NFKB2RELACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | GAA 4315/4885NFKB1 3452/4885NFKB2 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.